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a b s t r a c t
Of the many health beneﬁts attributed to selenium, the one that has received the most attention is its role in
cancer prevention. Selenium-containing proteins (selenoproteins) have been shown in recent years to have
roles in cancer prevention. However, selenoproteins have diverse functions and their view as antioxidants is
oversimpliﬁed. Some selenoproteins appear to have a split personality in having roles both in preventing and
promoting cancer. The contrasting roles of one selenoprotein, thioredoxin reductase 1, in cancer are
discussed in detail, but as also noted, at least one other selenoprotein may also have such a dual function. In
addition, we discuss examples of inhibition of cancer development by selenoprotein deﬁciency in mouse
models. These studies highlight the complex nature of selenium in relation to cancer.
Published by Elsevier B.V.

1. Introduction
Among the many health beneﬁts attributed to selenium that
include roles in cancer prevention, inhibiting viral expression,
delaying the progression of AIDS in HIV-infected patients, preventing
heart disease and other cardiovascular and muscle disorders, slowing
the aging process, and having roles in mammalian development, male
reproduction and immune function [1], the one that has received the
most attention is its role as a cancer chemopreventive agent.
The manner in which this element acts in preventing cancer is
poorly understood; and there has been considerable debate in the
ﬁeld whether selenium-containing proteins (selenoproteins) or low
molecular weight (non-protein) selenocompounds, or both, are
effective in preventing cancer [e.g., see [2–11]. Investigators favoring
the proposal that selenocompounds have more inﬂuence have
argued that the effectiveness of selenium in cancer prevention is
seen only following supplementation of the diet with amounts of
selenium that are signiﬁcantly higher than the normal dietary intake
[12] and these higher amounts do not increase selenoprotein levels
in circulating blood [13,14]. Although substantial experimental data
have been obtained supporting the selenocompound proposal [e.g., see
[2–5,7,11], many of these studies were carried out in mice supplemented with selenocompounds at levels that could not be used in humans
for safety reasons and at the time when an in-depth understanding of
only a limited number of selenoproteins was available. We now know
that humans have 25 selenoprotein genes and rodents 24 [15].

⁎ Corresponding author. Tel.: +1 301 496 2797; fax: +1 301 435 4957.
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Our knowledge about the roles of several selenoproteins in cancer
is rapidly developing from different approaches that include biochemical, genetic and animal studies. These studies have provided
strong evidence that selenoproteins play a major role in cancer
prevention and other health beneﬁts in a number of settings and
model systems [e.g., see [1,6,8–11,16–19]. For example, two recent
studies involving mouse models have shown a direct role of
selenoproteins in colon [20] and prostate [21] cancers. Interestingly,
one of these studies demonstrated that low molecular selenocompounds also had a role in cancer prevention [20].
Several excellent articles in this special issue on “Selenoprotein
expression and function” cover related topics on the roles of
selenoproteins in cancer. In the present review, we highlight the
complexity of the roles of selenium in cancer and discuss selenoproteins that appear to have roles in both preventing and promoting
cancer. We have used thioredoxin reductase 1 (TR1) as a model
example to examine the possible molecular mechanisms of how a
single protein can have such opposing functions. Finally, in contrast to
the well-established role of selenium in preventing cancer, we discuss
incidences where selenium deﬁciency may inhibit tumorigenesis.
2. Selenoproteins harboring a split personality in their roles in
cancer
It is becoming more and more apparent that some selenoproteins
can serve roles as both a cancer preventing agent and, once the
malignancy is initiated, as a cancer promoting agent [e.g., see [22] and
references therein]. We will focus on one such selenoprotein, TR1, and
also consider another selenoprotein, the 15 kDa selenoprotein
(Sep15).

0304-4165/$ – see front matter. Published by Elsevier B.V.
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3. Thioredoxin reductase 1 (TR1)
TR1 is among the most investigated selenoproteins due to its
essential role in the thioredoxin system as the enzyme that controls
the redox state and therefore the function of thioredoxin by keeping
this protein in the reduced state [23]. TR1 is considered as one of the
major redox regulators in mammalian cells [24,25] with roles in cell
proliferation, transcription, DNA repair and angiogenesis [26–29]. It
also contributes to antioxidant defense and acts as a redox regulator of
cell signaling [24–29]. In mammals, TR1 is an essential enzyme that
plays a major role in embryogenesis [30]. It is expressed in all cell
types and organs and its Sec moiety, which is the C-terminal
penultimate residue [31], is required for catalytic activity [e.g., see
[32,33]]. Since TR1 acts by reducing Trx1 and other redox regulators in
cells [23–25], and since oxidative stress is one of the principal
characteristics of cancer cells [26–29], this selenoenzyme most
certainly serves as a cancer preventive protein [34]. The observations
that TR1 activates the p53 tumor suppressor, manifests other tumor
suppressor activities [35], and is speciﬁcally targeted by carcinogenic
electrophilic compounds [36] also suggest that TR1 plays a major role
in cancer prevention. On the other hand, TR1 has a role in promoting
cancer. Its over-expression in many cancer cell lines and cancers
[26–29], targeting by a number of anti-cancer drugs and potent
inhibitors that alter cancer-related properties of malignant cells
[26–29,37,38] and its deﬁciency that reverses cell morphology and
other cancer characteristics [22,39] all point to a role of TR1 in cancer
promotion. These observations have led to the proposal that TR1 is a
target for cancer therapy [22,26–29,34,37–39].
Whether the cancer promoting or cancer preventing properties of
TR1 have greater inﬂuence on the fate of a cell may be difﬁcult to
predict. An elucidation of how TR1 exerts such contrasting effects,
however, may lead to a better means of utilizing these properties in
cancer prevention and/or cancer therapy.
To examine how TR1 functions metabolically in preventing cancer
and then switching its role to promoting cancer, we initially knocked
down this protein in a mouse lung cancer cell line, LLC1 [39]. Many of
the cell's malignant properties were reversed including morphology,
anchorage-independent growth and expression of two cancer-related
mRNAs, Hfg and Opn1. Interestingly, mice injected with the knocked
down TR1 cells manifested a pronounced reduction in tumor
progression and metastasis compared to mice injected with control,
malignant cells as shown in the Figure. Furthermore, tumors arising in
mice injected with TR1 knockdown cells were much smaller in size
than the tumors from mice injected with control, malignant cells, and
most importantly, they had lost their targeting construct (Fig. 1).
Clearly, over-expression of TR1 in these cancer cells is required to
maintain their tumorigenic properties and TR1 appears to be a major
driver in this cancer model. In addition, examination of a number of
human and mouse cancer cell lines showed that they had elevated
levels of TR1, but not other selenoproteins, and knockdown of TR1 in
these cells disrupted characteristics of malignancy, albeit to varying
degrees ([22]; and Yoo, M.-H., Carlson, B.A., Gladyshev, V.N., and
Hatﬁeld, D.L., unpublished data). The latter data demonstrate that
interference with TR1 function in cancer cells may disrupt the
malignancy process and further substantiate TR1 as a pro-cancer
protein and a target for cancer therapy.
Although the above studies show a direct connection between
enriched TR1 levels in cancer cells and the malignancy process, they
did not elucidate the molecular basis for the role of this protein in
promoting malignancy. One limitation of these studies is that they did
not have a parental, normal cell line for comparison. To overcome this
limitation, the consequences of targeting the knockdown of TR1 in an
oncogenic k-ras cell line were compared to the parental (normal) cell
line, and it was found that the resulting morphological changes in the
knockdown cells were more characteristic of the parental, normal
cells [22]. The k-ras, TR1 knockdown cells, when grown in serum-

deﬁcient medium, lost their self-sufﬁciency growth properties and
manifested a defective progression in their S growth phase. Furthermore, they had a decreased expression of DNA polymerase α which is
an enzyme important in DNA replication. The results demonstrate that
over-expression of TR1 has a direct role in many of the requirements
governing the malignancy process and suggest avenues for the
inhibition of cancer [e.g., see [22]].
4. Selenoprotein 15 (Sep15)
Sep15 was discovered in the late 1990s in human T-cells as a
15 kDa selenoprotein [40]. It was found to exist in a complex with
UDP-glucose:glycoprotein glucosyltransferase (UGTR), a protein that
is involved in the quality control of protein folding [41], and to be
localized in the endoplasmic reticulum of mammalian cells [42].
Recent data show that Sep15 may play a role in the reduction or
isomerization of disulﬁde bonds of glycoprotein substrates of UGTR
[43]. The gene for Sep15 consists of ﬁve exons and four introns and is
localized on chromosome 1p31 that is a locus often deleted or
mutated in human cancers [44]. The highest levels of Sep15 were
found in human and mouse liver, kidney, prostate, brain and testes,
but its levels were reduced in hepatocarcinoma and a cancer
prostate cell line [44]. Interestingly, two polymorphic sites occur in
the human Sep15 gene at nucleotide positions 811 (C/T) and 1125
(A/G) in the 3′UTR and one of these, an A1125/G1125 polymorphism,
is present in the Sep15 selenocysteine insertion sequence (SECIS)
element [40]. These polymorphisms manifest different responses to
selenium supplementation and efﬁciency of Sec incorporation into
protein [44,45], as well as differences in allele frequencies among
different ethnic groups and among breast or head and neck tumors
within African Americans [45]. In addition, Sep15 was found to be
down-regulated more than 50% in malignant mesothelioma cells
and, although growth was inhibited and apoptosis induced in
response to selenium in a dose-dependent manner in malignant
cells, those cancerous cells carrying a knockdown of Sep15 were less
responsive to selenium [46]. Furthermore, malignant mesothelioma
cells carrying the Sep15 A1125 variant were less responsive to the
effects of selenium than the corresponding cells expressing the other
polymorphic form. Among smokers, an increase in lung cancer risk
was observed in individuals with a GG or GA1125 genotype compared
to those individuals with an AA1125 genotype [47].
Many of these studies suggested a role of Sep15 in cancer
development and/or risk that included its chromosomal location, its
variation in expression patterns with the different polymorphic
forms wherein they responded differently to selenium levels and
protein incorporation, and in its expression patterns in normal and
malignant tissues and cells. In spite of these observations suggesting
a role of Sep15 in cancer protection, it was recently observed that
Sep15 knockdown in a colon cancer cell line reversed many of the
cancer characteristics suggesting that it has a dual personality in
colon cancer ([48]; and Irons, R., Tsuji, P., Ouyang, P., Yoo, M.-H., Xu,
X.-M., Carlson, B.A., Hatﬁeld, D.L., Gladyshev, V.N., and Davis, C.D.,
unpublished data).
5. Implication of selenoprotein deﬁciency in preventing
tumorigenesis
An additional issue relevant to the contrasting roles of selenium/
selenoproteins in cancer is the role of selenium deﬁciency in this
process. On the surface, the possibility that selenium deﬁciency has
anti-cancer effects is contrary to the dominant views on the role of
selenium in cancer prevention, but there is emerging evidence that
this may be the case in some cancers. One study involved an
examination of the progression of peritoneal plasmacytoma (PCT) in
selenium-deﬁcient mice [49]. The development of PCT in mice was
dependent on chronic peritoneal inﬂammation wherein PCT was
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Fig. 1. Tumorigenicity and metastasis of TR1 knockdown LLC1 cells. Mice were injected in either (A) the ﬂank or (B) a tail vein with LLC1 cells expressing a control vector (designated
control in the ﬁgure) or the same vector, but encoding the TR1 knockdown sequence (see Ref. [39] for details). In A1, tumor formation was monitored over a two week period and
mice were euthanized and tumors weighed. In A2, Western blot analysis of TR1 levels in the two tumors in A1 (upper panel) and PCR analysis of genomic DNA from the tumors in A1
(lower panel). Clearly, TR1 is present in the smaller tumor generated in the TR1 knockdown LLC1 cells (upper panel). PCR analysis was carried out to identify the presence or absence
of the control or knockdown vector in the tumor and the data show that the TR1 knockdown vector is lost from the tumor formed in mice injected with the knockdown vector (lower
panel). Overall, these data demonstrate that TR1 expression is required for tumor formation in this experimental model. In A3, Western blot analysis of TR1 in LLC1 cells that were
transfected with either the control vector or the TR1 knockdown vector prior to the injections of these cells into mice. The data illustrate the expression of TR1 in injected cells
encoding the control or knockdown vector. In B1, metastasis was assessed after four weeks in the lungs of mice injected in their tails with LLC1 cells encoding either the control vector
or the TR1 knockdown vector. The data show that TR1 expression is required for tumor formation in lungs following metastasis. In B2, tissue slices from the lungs in B1 are shown
wherein pathological changes were observed in the tissue from of the control mice (see arrows), but not in the mice carrying the TR1 knockdown vector. The ﬁgure was taken with
slight modiﬁcation from Ref. [39] with permission from the Journal of Biological Chemistry.

induced by injection with pristane. Virtually none of the mice injected
with pristane and maintained on a selenium-deﬁcient diet developed
PCT, whereas about 40% of the control mice maintained on two
different selenium-adequate diets developed PCT. The investigators
suggested that selenium in the form of selenoproteins was implicated
in PCT development and that selenoprotein inhibition might be a
means of preventing cancers associated with chronic inﬂammation
such as PCT [49].
Selenoprotein deﬁciency, as well as high levels of selenium
compounds, were also reported to inhibit liver tumor formation in
transforming growth factor (TGFα)/c-Myc oncogene transgenic mice
[50]. The development of hepatocarcinomas is well-established in
the TGFα/c-Myc transgenic mouse line wherein co-expression of
two transgenes results in high penetrance of liver cancer in about 6–
8 months [51]. Mice carrying both transgenes were maintained on a
selenium-deﬁcient, yeast-based diet or the same diet supplemented
with either 0.1 ppm, 0.4 ppm or 2.25 ppm selenium as sodium
selenite [50]. Relatively few tumors were found in the 0 ppm and
2.25 ppm selenium-supplemented diets, whereas many more were
found in the 0.1 and 0.4 ppm selenium groups. The highest incidence
was found in the 0.4 ppm selenium group and the fewest in the
0 ppm group. It appears that 0 ppm and 2.25 ppm diets were
associated with induction of detoxiﬁcation genes due to selenoprotein deﬁciency and selenite toxicity, respectively. Both of these
dietary treatments also promoted apoptosis and inhibited cell
proliferation. These factors (alteration in selenoprotein levels,

enhanced detoxiﬁcation, apoptotic enhancement and cell propagation) likely contributed to the protection against tumor formation
[50]. Thus, alterations in selenoprotein expression may both
suppress or enhance malignancy depending on cell type and
genotype.
6. Concluding remarks
Although our knowledge is increasing at a dramatic pace in the
selenium ﬁeld (e.g., see this volume on “Selenoprotein expression and
function” and [1]), we are only beginning to learn about the
consequences of selenium imbalance and the role of selenium in
promoting cancer through the action of selenoproteins, as well as the
role of selenium deﬁciency in inhibiting speciﬁc malignancies. TR1
and Sep15, and perhaps other selenoproteins, appear to act in cancer
prevention in normal cells, but in malignancy their roles are switched
to cancer promotion. An analysis of TR1 is beginning to shed light on
the consequences of the over-expression of this selenoenzyme on
growth, metastasis and resistance against cellular stress in cancer cells
[e.g., see [22]]. However, there is still much to be done in this area.
Similarly, there are, to our knowledge, only two examples of selenium
deﬁciency causing cancer inhibition [49,50], but clearly, selenium may
be the culprit as its abundance is what may be promoting such
disorders at least in some situations. Most likely, there are other
malignancies that might be reduced by selenium deﬁciency, and
therefore, selenoprotein, inadequacy.
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It is tempting to speculate on a possible mechanism of how
selenium deﬁciency may inhibit tumorigenesis. One possibility would
seem that the expression of those selenoproteins which are more
susceptible to selenium status (e.g., stress-related selenoproteins
[10,52,53]) may play a role in this process. Whether the reduced levels
of selenoproteins result in compensatory or adaptive changes in other
protective systems during the initiation stage of carcinogenesis, or
they inhibit the growth of already established tumors, should be
addressed in further research.
An important point to emphasize from an examination of the role
of selenium in promoting cancer is that our understanding of
selenium biology is by in large inadequate. Numerous human clinical
trials involving thousands of subjects have administered seleniumsupplemented diets and more are likely to be undertaken. It would
seem, in light of our lack of knowledge in many areas of selenium
function, to be more prudent to wait for additional genetic,
mechanistic and animal studies before undertaking large, very
expensive human trials.
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